Bio Stocks™· @BioStocks · X·· 2 天前评分90
正文 · 机器翻译
$RVMD 在 #ESMO26 上展示 RASONQUE 在既往治疗过的转移性胰腺癌亚组中的 OS 数据 $TNGX
亚组分析显示，RASONQUE 在关键亚组中持续提供 OS 获益，包括未检出肿瘤 RAS 突变的患者
https://www.globenewswire.com/news-release/2026/10/23/3387179/0/en/revolution-medicines-presents-overall-survival-data-for-rasonque-daraxonrasib-across-subgroups-in-previously-treated-metastatic-pancreatic-cancer-at-esmo-2026.html
5144 浏览 · 18 赞 · 1 转发 · 0 回复
会议摘要
LBA82按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.org来源：Bio Stocks™ · x.com